[go: up one dir, main page]

PL2638033T3 - Związki użyteczne w inhibicji chk1 - Google Patents

Związki użyteczne w inhibicji chk1

Info

Publication number
PL2638033T3
PL2638033T3 PL11788263T PL11788263T PL2638033T3 PL 2638033 T3 PL2638033 T3 PL 2638033T3 PL 11788263 T PL11788263 T PL 11788263T PL 11788263 T PL11788263 T PL 11788263T PL 2638033 T3 PL2638033 T3 PL 2638033T3
Authority
PL
Poland
Prior art keywords
compounds useful
inhibiting chk1
chk1
inhibiting
compounds
Prior art date
Application number
PL11788263T
Other languages
English (en)
Inventor
Sajan Joseph
Susanta Samajdar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2638033T3 publication Critical patent/PL2638033T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08Acetic acid
    • C07C53/10Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/06Oxalic acid
    • C07C55/07Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/10Succinic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL11788263T 2010-11-08 2011-11-01 Związki użyteczne w inhibicji chk1 PL2638033T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41113710P 2010-11-08 2010-11-08
EP11788263.9A EP2638033B1 (en) 2010-11-08 2011-11-01 Compounds useful for inhibiting chk1
PCT/US2011/058692 WO2012064548A1 (en) 2010-11-08 2011-11-01 Compounds useful for inhibiting chk1

Publications (1)

Publication Number Publication Date
PL2638033T3 true PL2638033T3 (pl) 2015-09-30

Family

ID=45044707

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11788263T PL2638033T3 (pl) 2010-11-08 2011-11-01 Związki użyteczne w inhibicji chk1

Country Status (22)

Country Link
US (1) US9067920B2 (pl)
EP (1) EP2638033B1 (pl)
JP (1) JP5792316B2 (pl)
KR (1) KR101533166B1 (pl)
CN (1) CN103180311B (pl)
AR (1) AR083575A1 (pl)
AU (1) AU2011326230B2 (pl)
BR (1) BR112013010009B1 (pl)
CA (1) CA2816944C (pl)
DK (1) DK2638033T3 (pl)
EA (1) EA022096B1 (pl)
ES (1) ES2541414T3 (pl)
HR (1) HRP20150530T1 (pl)
JO (1) JO3145B1 (pl)
ME (1) ME02119B (pl)
MX (1) MX2013005181A (pl)
PL (1) PL2638033T3 (pl)
PT (1) PT2638033E (pl)
RS (1) RS54012B1 (pl)
SI (1) SI2638033T1 (pl)
TW (1) TWI501956B (pl)
WO (1) WO2012064548A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
JP6794609B2 (ja) 2016-02-04 2020-12-02 ファーマエンジン インコーポレーテッドPharmaengine, Inc. チェックポイントキナーゼ1(chk1)阻害剤として有用な3,5−二置換ピラゾール、並びにその調製及び用途
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
US12410154B2 (en) 2020-11-30 2025-09-09 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
JPWO2023120696A1 (pl) 2021-12-24 2023-06-29
CN119403571A (zh) * 2022-05-27 2025-02-07 住友制药株式会社 对免疫检查点抑制剂示出治疗抗性的癌症的治疗药
WO2024216154A1 (en) * 2023-04-14 2024-10-17 Blueprint Medicines Corporation Cdk2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412820A (pt) * 2003-07-25 2006-09-26 Pfizer compostos de aminopirazol e utilização como inibidores de chk1
RU2397168C2 (ru) * 2004-01-05 2010-08-20 Астразенека Аб Производные тиофена в качестве ингибиторов снк 1
MXPA06014129A (es) * 2004-06-04 2007-03-07 Arena Pharm Inc Derivados de arilo y heteroarilo sustituidos como moduladores del metabolismo y profilaxis y tratamiento de trastornos relacionados con los mismos.
JP2008540391A (ja) * 2005-05-05 2008-11-20 アストラゼネカ アクチボラグ ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
WO2006135604A2 (en) * 2005-06-09 2006-12-21 Merck & Co., Inc. Inhibitors of checkpoint kinases
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
PA8850801A1 (es) * 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1

Also Published As

Publication number Publication date
EA201390499A1 (ru) 2013-08-30
US20130190262A1 (en) 2013-07-25
CA2816944A1 (en) 2012-05-18
US9067920B2 (en) 2015-06-30
TWI501956B (zh) 2015-10-01
DK2638033T3 (en) 2015-04-27
AR083575A1 (es) 2013-03-06
KR101533166B1 (ko) 2015-07-01
PT2638033E (pt) 2015-06-01
KR20130099146A (ko) 2013-09-05
JO3145B1 (ar) 2017-09-20
SI2638033T1 (sl) 2015-05-29
AU2011326230B2 (en) 2015-02-19
TW201305138A (zh) 2013-02-01
EP2638033B1 (en) 2015-04-08
RS54012B1 (sr) 2015-10-30
CN103180311A (zh) 2013-06-26
ES2541414T3 (es) 2015-07-20
MX2013005181A (es) 2013-10-17
CN103180311B (zh) 2014-08-20
WO2012064548A1 (en) 2012-05-18
AU2011326230A1 (en) 2013-05-09
HRP20150530T1 (hr) 2015-06-19
BR112013010009B1 (pt) 2021-10-19
JP5792316B2 (ja) 2015-10-07
CA2816944C (en) 2015-12-22
BR112013010009A2 (pt) 2020-09-29
JP2013541586A (ja) 2013-11-14
EP2638033A1 (en) 2013-09-18
EA022096B1 (ru) 2015-10-30
ME02119B (me) 2015-10-20

Similar Documents

Publication Publication Date Title
IL249578A0 (en) organic compounds
IL223783A0 (en) Pro-neurogenic compounds
GB201008134D0 (en) Compounds
GB201015949D0 (en) Compounds
PL2619208T3 (pl) Związki imidazotriazynonu
IL225770A0 (en) Heterocyclic compounds
PL2648516T3 (pl) Podstawione związki pirydynono-pirydynylowe
GB201007347D0 (en) Compounds
SI2638033T1 (sl) Spojine uporabne za inhibicijo chk1
EP2649050A4 (en) LINKS
GB201002563D0 (en) Compounds
GB201008209D0 (en) Compounds
GB201001688D0 (en) Compounds
GB201021584D0 (en) Organic compounds
GB201002216D0 (en) Compounds
GB201001796D0 (en) Compounds
GB201020070D0 (en) Organic compounds
EP2544690A4 (en) ARYLVINYLAZACYCLOALCANE COMPOUNDS FOR CONSTIPATION
GB201018171D0 (en) Organic compounds
GB201015537D0 (en) Compounds
GB201008210D0 (en) Compounds
GB201021494D0 (en) Compounds
GB201013507D0 (en) Compounds
GB201000831D0 (en) Compounds
GB201005727D0 (en) Compounds